Literature DB >> 7739012

Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor.

E A Biessen1, D M Beuting, H C Roelen, G A van de Marel, J H van Boom, T J van Berkel.   

Abstract

High-affinity ligands for the asialoglycoprotein receptor, which is uniquely localized on the parenchymal liver cell and recognizes oligoantennary galactosides, might be utilized as homing device to specifically target drugs or genes to parenchymal liver cells. In the present study, the synthesis of galactose-terminated triantennary glycosides, provided with various spacers between the beta-galactopyranosyl moieties and the branching point of the dendrite, is described. N-[Tris[[(methylthio)methoxy]methyl]methyl]-N alpha-[1-(6- methyladipy)]glycinamide (3b) was glycosylated with monogalactosyl derivatives, containing propanediol or ethylene glycol units as hydrophilic spacer moieties, to yield the corresponding cluster galactosides. To determine the affinity of the cluster galactosides for the asialoglycoprotein receptor, we have performed competition studies of [125I]ASOR binding, a specific ligand for the asialoglycoprotein receptor, to isolated parenchymal cells. The affinity for the asialoglycoprotein receptor significantly increased with increasing spacer length. N-[[[Tris-O-(beta-D-galactopyranosyl)-3,6,9-trioxaunde- canoxy]methoxy]methyl]-N-alpha-[1-(6-methyladipyl)]glycinami de (4e), a cluster galactoside provided with a 20 A spacer, possessed an at least 2000-fold higher affinity for the receptor than N-[[tris-O-(beta-D-galactopyranosyl)methyl]methyl]-N alpha-[1-(6- methyladipyl)]glycinamide (4a), a cluster galactoside lacking the spacer. It is concluded that vicinal galactosyl moieties within a cluster galactoside are more optimal recognized by the galactose binding sites of the asialoglycoprotein receptor upon proper spacing. The most potent galactoside, TG(20A), may constitute an attractive targeting device for the specific delivery of drugs and/or genes to the parenchymal liver cell.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7739012     DOI: 10.1021/jm00009a014

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  24 in total

1.  A novel hepatic-targeting system for therapeutic cytokines that delivers to the hepatic asialoglycoprotein receptor, but avoids receptor-mediated endocytosis.

Authors:  Haruya Sato; Yukio Kato; Eiko Hayasi; Tomoyuki Tabata; Manabu Suzuki; Yoshiyuki Takahara; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

2.  A rapid two-step method for isolation of functional primary mouse hepatocytes: cell characterization and asialoglycoprotein receptor based assay development.

Authors:  Mariano Severgnini; Jennifer Sherman; Alfica Sehgal; Narayanannair K Jayaprakash; Justin Aubin; Gang Wang; Ligang Zhang; Chang G Peng; Kristina Yucius; Jim Butler; Kevin Fitzgerald
Journal:  Cytotechnology       Date:  2011-11-22       Impact factor: 2.058

3.  Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics.

Authors:  Jinjin Zhang; Jered C Garrison; Larisa Y Poluektova; Tatiana K Bronich; Natalia A Osna
Journal:  Biomaterials       Date:  2015-08-08       Impact factor: 12.479

4.  Ligands of the asialoglycoprotein receptor for targeted gene delivery, part 1: Synthesis of and binding studies with biotinylated cluster glycosides containing N-acetylgalactosamine.

Authors:  Ulrika Westerlind; Jacob Westman; Elisabeth Törnquist; C I Edvard Smith; Stefan Oscarson; Martina Lahmann; Thomas Norberg
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

Review 5.  Delivery materials for siRNA therapeutics.

Authors:  Rosemary Kanasty; Joseph Robert Dorkin; Arturo Vegas; Daniel Anderson
Journal:  Nat Mater       Date:  2013-11       Impact factor: 43.841

6.  Synthesis and in vitro inhibition properties of siRNA conjugates carrying glucose and galactose with different presentations.

Authors:  Anna Aviñó; Sandra M Ocampo; Ricardo Lucas; José J Reina; Juan Carlos Morales; José Carlos Perales; Ramon Eritja
Journal:  Mol Divers       Date:  2011-01-26       Impact factor: 2.943

7.  Evaluation of pullulan-functionalized doxorubicin nanoparticles for asialoglycoprotein receptor-mediated uptake in Hep G2 cell line.

Authors:  Swati A Guhagarkar; Sharmila B Majee; Abdul Samad; Padma V Devarajan
Journal:  Cancer Nanotechnol       Date:  2011-01-27

8.  Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.

Authors:  D Scott Wilbur; Steven I Park; Ming-Kuan Chyan; Feng Wan; Donald K Hamlin; Jaideep Shenoi; Yukang Lin; Shani M Wilbur; Franz Buchegger; Anastasia Pantelias; John M Pagel; Oliver W Press
Journal:  Bioconjug Chem       Date:  2010-07-21       Impact factor: 4.774

Review 9.  Knocking down disease: a progress report on siRNA therapeutics.

Authors:  Anders Wittrup; Judy Lieberman
Journal:  Nat Rev Genet       Date:  2015-09       Impact factor: 53.242

Review 10.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.